Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Protein therapeuticsSmall molecule

Accord BioPharma General Information

US specialty division of Intas Pharmaceuticals focused on biosimilars and specialty products. Currently markets CAMCEVI (leuprolide) and is acquiring UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Raleigh, North Carolina
United States

Drug Pipeline

leuprolide
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Accord BioPharma's pipeline data

Book a demo

Key Partnerships

Bio-Thera Solutions, Coherus BioSciences

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Accord BioPharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Accord BioPharma's complete valuation and funding history, request access »